Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.

@article{Linnebjerg2011ExenatideP,
  title={Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.},
  author={Helle Linnebjerg and Prajakti A. Kothare and Mary Seger and Anne M Wolka and Malcolm I. Mitchell},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2011},
  volume={49 2},
  pages={99-108}
}
OBJECTIVE This study evaluated pharmacokinetics, pharmacodynamics,safety, and tolerability of single doses of exenatide in elderly Type 2 diabetes (T2D)patients. METHODS This placebo-controlled,patient-blind, crossover study compared elderly patients (≥ 75 y, n = 15) to controls( ≥ 45 to ≤ 65y, n = 15) with T2D. Patients were randomized to single… CONTINUE READING